H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Duration: January 14, 2011
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $3,310,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Office of Management & Budget (OMB), Food & Drug Administration (FDA), White House Office, Commerce - Dept of (DOC), Centers For Medicare and Medicaid Services (CMS), U.S. Senate,, Centers For Medicare and Medicaid Services (CMS),, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Melanie Nathanson Policy Analyst, Sr. Policy Advisor- Sen. Bob Graham
Senior Legislative Asst. - Rep Sander Levin
Megan Hauck Pd intern, LC, Scheduler, LA, Pol Advsr. - Sen. Don Nickles
Deputy Asst. Secretary - DHHS
Special Asst. to Potus - White House
Sr. Policy Advisor - Senator Mitch McConnell
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on April 7.
Original Filing: 301547013.xml
Lobbying Issues
H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large.
H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications.
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Dec. 31, 2023.
Original Filing: 301521041.xml
Lobbying Issues
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
HR 6363 - Further Continuing Appropriations and other Extenders Act - Support for critical government programs remaining operational and available.
HR 5860 - Continuing Appropriations Act of FY 2024 and other Extensions Act - Support for critical government programs remaining operational and available.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
HR 6363 - Further Continuing Appropriations and other Extenders Act - Support for critical government programs remaining operational and available.
HR 5860 - Continuing Appropriations Act of FY 2024 and other Extensions Act - Support for critical government programs remaining operational and available.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees.
HR 6363 - Further Continuing Appropriations and other Extenders Act - Support for critical government programs remaining operational and available.
HR 5860 - Continuing Appropriations Act of FY 2024 and other Extensions Act - Support for critical government programs remaining operational and available.
S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients.
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Oct. 7, 2023.
Original Filing: 301498353.xml
Lobbying Issues
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors.
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on July 4, 2023.
Original Filing: 301472899.xml
Lobbying Issues
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare.
S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications.
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on April 11, 2023.
Original Filing: 301450525.xml
Lobbying Issues
S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission.
S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest.
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug supply chain integrity and transparency.
Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Jan. 2, 2023.
Original Filing: 301424602.xml
Lobbying Issues
HR 2617 - Consolidated Appropriations Act for Fiscal Year 2023 - Issues related to ensuring high quality/ high value pharmacy benefits in the Medicare program.
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2617 - Consolidated Appropriations Act for Fiscal Year 2023 - Issues related to ensuring high quality/ high value pharmacy benefits in the Medicare program.
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2617 - Consolidated Appropriations Act for Fiscal Year 2023 - Issues related to ensuring high quality/ high value pharmacy benefits in the Medicare program.
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Issues and legislative vehicles related to capping the price of Insulin.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Oct. 8, 2022.
Original Filing: 301401988.xml
Lobbying Issues
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule.
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Issues and legislative vehicles related to capping the price of Insulin.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on July 2, 2022.
Original Filing: 301377156.xml
Lobbying Issues
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain.
S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work.
S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule.
S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans.
Issues and legislative vehicles related to capping the price of Insulin.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on April 17, 2022.
Original Filing: 301357890.xml
Lobbying Issues
H.R. 2571 Consolidated Appropriations Act for Fiscal Year 2022 - Issues related to the use of rebates and other cost savings tools used by pharmacy benefit managers
Issues and legislative vehicles related to capping the price of Insulin.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2571 Consolidated Appropriations Act for Fiscal Year 2022 - Issues related to the use of rebates and other cost savings tools used by pharmacy benefit managers
Issues and legislative vehicles related to capping the price of Insulin.
Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR).
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Jan. 7, 2022.
Original Filing: 301320571.xml
Lobbying Issues
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
H.R. 3684 - Infrastructure Investment and Jobs Act Act - Support for delay of the Trump Administration's Rebate rule
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
H.R. 3684 - Infrastructure Investment and Jobs Act Act - Support for delay of the Trump Administration's Rebate rule
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on Oct. 10, 2021.
Original Filing: 301297645.xml
Lobbying Issues
Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.
H.R. 3684 - INVEST in America Act - Support for delay of the Trump Administration's Rebate rule
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Build Back Better Act - Support of full repeal of the Trump Administration's Medicare Rebate Rule.
H.R. 3684 - INVEST in America Act - Support for delay of the Trump Administration's Medicare Rebate rule
PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on July 13, 2021.
Original Filing: 301275485.xml
Lobbying Issues
PL 117-2 - The American Rescue Plan Act - Issues related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Issues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.
Agencies Lobbied
U.S. Senate
Lobbying Issues
PL 117-2 - The American Rescue Plan Act Implementation- Issues related to policies that increase access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Issues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.
Agencies Lobbied
U.S. Senate
Lobbying Issues
PL 117-2 - The American Rescue Plan Act Implementation - Issues related to policies focused on increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Issues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $70,000. The report was filed on April 14, 2021.
Original Filing: 301253236.xml
Lobbying Issues
PL 177-2 - The American Rescue Plan Act - Issues related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.
Issues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2020
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 6, 2021.
Original Filing: 301229002.xml
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.
PL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.
H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of a Medicare drug discount card and the Medicare rebate rule.
PL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.
PL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 11, 2020.
Original Filing: 301208675.xml
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.
H.R. 8406 - The HEROES ACT (modified) - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID-19 pandemic.
Senate HEALS Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of a Medicare drug discount card and the Medicare rebate rule.
H.R. 8406 - The HEROES ACT (modified) - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID-19 pandemic as it impacts Medicare and Medicaid beneficiaries.
Senate HEALS Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic for Medicare and Medicaid beneficiaries.
H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications in the Medicare program.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic in the Medicare and Medicaid programs.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.
H.R. 8406 - The HEROES ACT (modified) - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID-19 pandemic.
Senate HEALS Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 3, 2020.
Original Filing: 301185267.xml
Lobbying Issues
H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications in the Medicare program.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic in the Medicare and Medicaid programs.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications.
H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.
H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 8, 2020.
Original Filing: 301154532.xml
Lobbying Issues
H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.
H.R. 6201 - Families First Coronavirus Response Act - Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2019
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 7, 2020.
Original Filing: 301103688.xml
Lobbying Issues
H.R. 1865 - Further Consolidated Appropriations Bill for FY 2020- policies focused on making prescription drugs more affordable, including the CREATES Act.
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Legislation being developed to reform Medicare Part B and D as they relate to lowering the costs of prescription medications.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Legislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1865 - Further Consolidated Appropriations Bill for FY 2020- policies focused on making prescription drugs more affordable, including the CREATES Act.
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Policies related to the reform of Medicare Part B and D specific to the price of prescription medications.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 13, 2019.
Original Filing: 301064905.xml
Lobbying Issues
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Legislation being developed to reform Medicare Part B and D as they relate to lowering the costs of prescription medications.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Legislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act.
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Policies related to the reform of Medicare Part B and D specific to the price of prescription medications.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 8, 2019.
Original Filing: 301043597.xml
Lobbying Issues
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Legislation being developed to reform Medicare Part B and D as they relate to lowering the costs of prescription medications.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Legislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Policies related to the reform of Medicare Part B and D specific to the price of prescription medications.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 4, 2019.
Original Filing: 301022750.xml
Lobbying Issues
CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.
C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 11, 2019.
Original Filing: 301003693.xml
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
FDA work on drug shortages and solutions.
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
FDA work on addressing drug shortages in the U.S.
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 2, 2018.
Original Filing: 300982442.xml
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 11, 2018.
Original Filing: 300963763.xml
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.
H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety.
S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 6, 2018.
Original Filing: 300942810.xml
Lobbying Issues
H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States.
H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States.
H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs)
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the cost of prescription medications in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States.
H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States.
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs)
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 14, 2018.
Original Filing: 300923613.xml
Lobbying Issues
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs)
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the cost of prescription medications in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs)
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to lowering the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 10, 2017.
Original Filing: 300902323.xml
Lobbying Issues
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery.
H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery.
Issues related to the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies.
Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D.
Issues related to the cost of prescription medications in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 10, 2017.
Original Filing: 300882956.xml
Lobbying Issues
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery.
H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery.
Issues related to the price of prescription medications in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Issues related to the cost of prescription medications in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 5, 2017.
Original Filing: 300862773.xml
Lobbying Issues
S. Con. Res. 3 - Budget Resolution for FY 2017 - Impact of reconciliation instructions on the prescription drug benefit and coverage for those covered through health care marketplaces and Medicaid beneficiaries.
S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices.
S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2016
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 12, 2017.
Original Filing: 300845542.xml
Lobbying Issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits in Medicare and Medicaid.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care in the Medicare program with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
P.L. 114-255 - 21st Century Cures Act - Issues focused on preventing opioid abuse.
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 17, 2016.
Original Filing: 300829030.xml
Lobbying Issues
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits in Medicare and Medicaid.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care in the Medicare program with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies.
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 11, 2016.
Original Filing: 300808083.xml
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits in Medicare and Medicaid.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care in the Medicare program with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 14, 2016.
Original Filing: 300791233.xml
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care in teh Medicare program with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction.
The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies.
FDA's March 31, 2016 biosimilar labeling guidance and additional work regarding biosimilars.
Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies.
Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and additional guidance and regulations focused on programs in the Exchanges that impact coverage and access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 5, 2016.
Original Filing: 300769202.xml
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754472.xml
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Issues related to patents and the treatment of prescription medications.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 13, 2015.
Original Filing: 300733701.xml
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.
Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 9, 2015.
Original Filing: 300713641.xml
Lobbying Issues
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks.
Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 14, 2015.
Original Filing: 300695611.xml
Lobbying Issues
CCIIO issuer letter and regulations focused on bids for 2015 and its impact on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Issues related to specialty pharmacy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 21st Century Cures legislative efforts
CCIIO issuer letter and regulations focused on bids for 2015 and its impact on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Issues related to specialty pharmacy.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
Nathanson+Hauck amended a lobbying report for representation of Pharmaceutical Care Management Association (PCMA) in Q42014 on Jan. 14, 2015.
Original Filing: 300695908.xml
Lobbying Issues
CCIIO issuer letter and regulations focused on bids for 2015 and its impact on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Issues related to specialty pharmacy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 21st Century Cures legislative efforts
CCIIO issuer letter and regulations focused on bids for 2015 and its impact on access to prescription medications and pharmacy networks.
Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.
Issues related to specialty pharmacy.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
Nathanson+Hauck amended a lobbying report for representation of Pharmaceutical Care Management Association (PCMA) in Q32014 on Oct. 9, 2014.
Original Filing: 300674933.xml
Lobbying Issues
Implementation of the Health Reform Law with a focus on regulations related to the medical loss ratio, Accountable Care Organizations, health care transparency, e-prescribing, and evolving the nation's health IT system.
Regulations and policies that focus on Medicare Part C and D
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulations and policies that focus on Medicare Part C and D
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 8, 2014.
Original Filing: 300674332.xml
Lobbying Issues
Implementation of the Health Reform Law with a focus on regulations related to the medical loss ratio, Accountable Care Organizations, health care transparency, e-prescribing, and evolving the nation's health IT system.
Regulations and policies that focus on Medicare Part C and D
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulations and policies that focus on Medicare Part C and D
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies related to stopping prescription medication diversion and abuse
Issues related to the creation of a biosimilar marketplace in the United States
Issues related to home delivery of prescription drugs
Issues related to Part D coverage for Medicare beneficiaries in hospice care
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 15, 2014.
Original Filing: 300656913.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2015 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
Regulatons pretaining to Medicare Part C&DMedicare Call Letter for Medicare PArt D bids for 2015 and its impact on access to prescripton medications and pharmacy networks.
Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
Issues related to regulations impacting Medicare Part C and D and pharmacy networks
President Obama's Budget for FY 2015 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 9, 2014.
Original Filing: 300633513.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2015 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
Regulatons pretaining to Medicare Part C&DMedicare Call Letter for Medicare PArt D bids for 2015 and its impact on access to prescripton medications and pharmacy networks.
Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
Issues related to regulations impacting Medicare Part C and D and pharmacy networks
President Obama's Budget for FY 2015 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 17, 2014.
Original Filing: 300618512.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2014 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
S. Con. Res. 8 - Senate Budget Resolution - Issues related to Medicare and MedicaidWork focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues in the law related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
H.R. 3204 Drug Quality and Security Act - Legislation to assress the security of the pharmaceutical supply chain and drug compounding practices.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Amendment H.J. Res 59 - Bipartisan Budget Act of 2013 - Potential provisions that impact access to prescription medications.
SGR Repeal - " Medicare Beneficiary Access Improvement Act of 2013" - Elements related to access to prescription medications.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
S. Con. Res. - Senate Budget Act for FY 2014 - focused on Medicare and Medicaid targets in the Budget
President Obama's Budget for FY 2014 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
H.R. 3204 Drug Quality and Security Act - Legislation to assress the security of the pharmaceutical supply chain and drug compounding practices.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Amendment H.J. Res 59 - Bipartisan Budget Act of 2013 - Potential provisions that impact access to prescription medications.
SGR Repeal - " Medicare Beneficiary Access Improvement Act of 2013" - Elements related to access to prescription medications.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Amendment H.J. Res 59 - Bipartisan Budget Act of 2013 - Potential provisions that impact access to prescription medications.
SGR Repeal - " Medicare Beneficiary Access Improvement Act of 2013" - Elements related to access to prescription medications.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 16, 2013.
Original Filing: 300594758.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2014 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
S. Con. Res. 8 - Senate Budget Resolution - Issues related to Medicare and MedicaidWork focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues in the law related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
H.R. 3204 Drug Quality and Security Act - Legislation to assress the security of the pharmaceutical supply chain and drug compounding practices.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
S. Con. Res. - Senate Budget Act for FY 2014 - focused on Medicare and Medicaid targets in the Budget
President Obama's Budget for FY 2014 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
H.R. 3204 Drug Quality and Security Act - Legislation to assress the security of the pharmaceutical supply chain and drug compounding practices.
Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 17, 2013.
Original Filing: 300574453.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2014 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
S. Con. Res. 8 - Senate Budget Resolution - Issues related to Medicare and MedicaidWork focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues in the law related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
S. Con. Res. - Senate Budget Act for FY 2014 - focused on Medicare and Medicaid targets in the Budget
President Obama's Budget for FY 2014 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain.
CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 29, 2013.
Original Filing: 300565874.xml
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options.
President Obama's budget for FY 2014 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx
S. Con. Res. 8 - Senate Budget Resolution - Issues related to Medicare and MedicaidWork focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues in the law related to PMBs in the context of Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to recent Medicare Call letter involving changes to polices in Medicare Part D
S. Con. Res. - Senate Budget Act for FY 2014 - focused on Medicare and Medicaid targets in the Budget
President Obama's Budget for FY 2014 - Focused on treatment of prescription medications at mail in Part D and FEHBPcont.
specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
March Medicare call letter and its impact on access to prescription drugs.
Issues related to the practice of providing coupons for prescription medications for seniors.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail.
Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 11, 2013.
Original Filing: 300527437.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
H.R. 4310 - National Defense Authorization Act for 2013 - Issues related to the utilization of mail order pharmacy for Tricare beneficiaries.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
cont.
Part D and PBM- related policies.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Issues related to the practice of giving coupons for certain prescription medications.S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
H.R. 4310 - National Defense Authorization Act for 2013 - Issues related to the utilization of mail order pharmacy for Tricare beneficiaries.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 17, 2012.
Original Filing: 300509278.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Issues related to the practice of providing coupons for prescription medications for seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
cont.
Part D and PBM- related policies.
Issues related to the practice of providing coupons for prescription medications to Medicare beneficiaries.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Issues related to the practice of giving coupons for certain prescription medications.S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 6, 2012.
Original Filing: 300481104.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
Monitoring potential provisions focused on Medicare Part D and PBM-focused policies for end of year wrap up bills.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
cont.
Part D and PBM- related policies.
Issues related to Medicare part D and other PBM-related policies as part of discussions of end of year wrap up legislation.
Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Issues related to the practice of giving coupons for certain prescription medications.S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 11, 2012.
Original Filing: 300458966.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
H. R. 3630 ( S. Amdt. 1465) - Temporary Payroll Tax Cut Continuation Act of 2011 - Monitoring potential provisions focused on Medicare Part D and PBM-focused policies.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Industry related issues being considered as part of the Prescription Drug and Generic Drug User Fee Act reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
H.R. 3630 (S. Admt. 1465) - Temporary Payroll Tax Cut Continuation Act of 2011-12 - Monitoring policies impacting Medicarecont.
Part D and PBM- related policies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Issues related to the practice of giving coupons for certain prescription medications.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Dec. 28, 2011.
Original Filing: 300433852.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions.
H. R. 3630 ( S. Amdt. 1465) - Temporary Payroll Tax Cut Continuation Act of 2011 - Monitoring potential provisions focused on Medicare Part D and PBM-focused policies.
Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
H.R. 3630 (S. Admt. 1465) - The Temporary Payroll Tax Cut Continuation Act of 2011 - Monitoring policies impacting Medicare cont.
Part D and PBM- related policies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 10, 2011.
Original Filing: 300411815.xml
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits.
H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act. Focused on pharmacy benefit provisions that could be included in both the Medicare and Medicaid arenas as they related to the work of Congress as it relates to the law.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 8, 2011.
Original Filing: 300386783.xml
Lobbying Issues
H.R. 1946 - The Community Pharmacy Fairness Act, which allows for an anti-trust exception for certain pharmacies.
Health Reform Law Implementation regulations with a focus on the treatment of Pharmacy Benefit Managers in the Medical Loss Ratio (MLR) rule and issues related to transparency.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1946 - The Community Pharmacy Fairness Act, which allows for an anti-trust exception for certain pharmacies.
Issues regarding the approval and coverage of a recently approved drug, Makena.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues regarding the approval and coverage of a recently approved drug, Makena.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Nathanson+Hauck lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 5, 2011.
Original Filing: 300360110.xml
Lobbying Issues
Health Reform Law implementation regulations with a focus on the treatment of Pharmacy Benefit Managers in the Medical Loss Ratio (MLR) rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues regarding the treatment of a newly approved drug, Makena, by the Medicaid program.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues regarding a newly approved drug, Makena, by the FDA.
Agencies Lobbied
Food & Drug Administration (FDA)
1st Quarter, 2011
Nathanson+Hauck filed a lobbying registration on Feb. 8, 2011 to represent Pharmaceutical Care Management Association (PCMA), effective Jan. 14, 2011.
Original Filing: 300357761.xml
Issue(s) they said they’d lobby about: Health reform implementation as it relates to prescription drug coverage, potential Rx related savings that can be applied to public insurance programs, and payment reform issues. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...